KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Research & Development (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Research & Development for 9 consecutive years, with $267.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 8.1% year-over-year to $267.0 million, compared with a TTM value of $1.0 billion through Dec 2025, changed 0.3%, and an annual FY2025 reading of $1.0 billion, up 1.5% over the prior year.
  • Research & Development was $267.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $247.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $748.0 million in Q4 2022 and bottomed at $175.0 million in Q3 2022.
  • Average Research & Development over 5 years is $267.1 million, with a median of $242.5 million recorded in 2021.
  • The sharpest move saw Research & Development surged 207.82% in 2022, then plummeted 69.79% in 2023.
  • Year by year, Research & Development stood at $243.0 million in 2021, then soared by 207.82% to $748.0 million in 2022, then tumbled by 69.79% to $226.0 million in 2023, then increased by 9.29% to $247.0 million in 2024, then rose by 8.1% to $267.0 million in 2025.
  • Business Quant data shows Research & Development for TEVA at $267.0 million in Q4 2025, $247.0 million in Q1 2025, and $247.0 million in Q4 2024.